Drug Trial Radar · NCT03264989
Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)
Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
57
Actual
Start
Dec 19, 2017
Primary completion
Jun 26, 2023
Study completion Jun 26, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 29, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the CSEG101A2202 study was to characterize the Pharmacokinetic (PK) and Pharmacodynamic (PD) of SEG101/crizanlizumab and to evaluate the safety and efficacy of SEG101/crizanlizumab in sickle cell disease (SCD) patients.
Conditions
- Sickle Cell Disease (SCD)
Interventions
crizanlizumabDrug
Crizanlizumab was administered IV infusion over 30 minutes at the assigned dose on Week 1 Day 1, Week 3 Day 1, and then Day 1 of every 4-week cycle. Cycle = 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic (PK): AUCd15 and AUCtau of Crizanlizumab at 5.0 mg/kg in Sickle Cell Disease (SCD) PatientsTime frame: 1st dose: Day 1: (pre-dose, 0.5, 1, 2, 4, 6 & 24 hours post dose, Days 4, 8 & 15; 5th dose: Day 1 (pre-dose, 0.5, 1, 2, 4, 6 and 24 hours post dose), Days 4, 8, 15, 22 & 29
- PK: Cmax of Crizanlizumab at 5.0 mg/kg in Sickle Cell Disease (SCD) PatientsTime frame: After the starting dose (Week 1) and after multiple doses (steady state, Week 15)
- Pre-dose Concentrations Prior to Each Study Drug DoseTime frame: Pre-dose at Day 1 on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51
- Percentage of P-selectin Inhibition After the Starting Dose (PD-AUCd15), After Multiple Doses (PD-AUCd29) of Crizanlizumab at 5.0 mg/kg in Sickle Cell Disease (SCD) PatientsTime frame: 1st dose: Day 1: (pre-dose, 0.5, 1, 2, 4, 6 & 24 hours post dose, Days 4, 8, 15; 5th dose: Day 1(pre-dose, 0.5, 1, 2, 4, 6 and 24 hours post dose), Days 4, 8, 15, 22 & 29
- Percentage of P-selectin Inhibition Prior to Each Study Drug Dose of Crizanlizumab at 5.0 mg/kg in Sickle Cell Disease (SCD) PatientsTime frame: Pre-dose on Day 1 for Weeks 3, 7, 11, 15, 19, 23, 27, 31,35, 39, 43, 47, 51 (at 0 hr or pre-dose)
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Orange, Florida
Novartis Investigative Site
Tampa, Florida
Childrens Healthcare of Atlanta .
Atlanta, Georgia
Augusta University Georgia Patient Treatment
Augusta, Georgia
University of Maryland Medical Ctr
Baltimore, Maryland
Childrens Hospital at Montefiore
The Bronx, New York
Duke University Medical Center Patient Treatment
Durham, North Carolina
East Carolina University East Carolina University
Greenville, North Carolina
Childrens Hospital Of Philadelphia Patient Treatment
Philadelphia, Pennsylvania
Medical Uni of South Carolina Medical Univ of SC
Charleston, South Carolina
M Francisco Gonzalez MD PA .
Columbia, South Carolina
Carolina Blood and Cancer Care of South Carolina
Rock Hill, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.